Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
University of Toronto
$105,000.00
The role of Liver X Receptors in diabetic nephropathy
EF 2009-10
Résumé
Diabetes affects 2 million Canadians and 246 million people worldwide. Diabetic nephropathy is a devastating consequence of poor glycemic control and is the leading cause of kidney failure in developed countries. It has been shown that the progression towards diabetic nephropathy is the result of dyslipidemia, and strongly correlated with high serum cholesterol levels. Liver X receptors (LXR-alpha and LXR-beta) are ligand activated transcription factors responsible for the regulation of genes involved in cholesterol and lipid metabolism. Interestingly, a number of genes dysregulated in diabetic nephropathy are also LXR target genes (ABCA1, PPAR-alpha, SREBP1c, FAS). We hypothesize that LXR activation will be protective against the onset of diabetic nephropathy. My first goal will be to develop a treatment protocol to induce diabetic nephropathy in a wild type (WT) mouse. Dyslipidemia will be induced using a high fat/high cholesterol (HF/HC) diet and hyperglycemia will be induced using streptozotocin (STZ). The basal phenotype of LXR-null mice under the HF/HC + STZ treatment protocol will than be characterized. This will determine whether the loss of LXR increases the susceptibility to diabetic nephropathy. Lastly, the effect of LXR activation on the progression and severity of diabetic nephropathy will be determined using WT mice subjected to HF/HC + STZ treatment in the presence or absence of LXR agonist. This will assess the ability of an LXR agonist to protect the kidney from lipid accumulation and thus prevent progression to diabetic nephropathy. By determining whether LXR activation can modulate lipid accumulation in the kidney, we hope to uncover a new therapeutic target for the treatment of diabetic nephropathy.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
206189
Name
Patel Monika
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
The role of Liver X Receptors in diabetic nephropathy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Cholesterol; Diabetes; Dyslipidemia; Kidney; Liver X Receptor; Metabolism; Nephropathy; Nutrition; Therapeutics
Abstract
Diabetes affects 2 million Canadians and 246 million people worldwide. Diabetic nephropathy is a devastating consequence of poor glycemic control and is the leading cause of kidney failure in developed countries. It has been shown that the progression towards diabetic nephropathy is the result of dyslipidemia, and strongly correlated with high serum cholesterol levels. Liver X receptors (LXR-alpha and LXR-beta) are ligand activated transcription factors responsible for the regulation of genes involved in cholesterol and lipid metabolism. Interestingly, a number of genes dysregulated in diabetic nephropathy are also LXR target genes (ABCA1, PPAR-alpha, SREBP1c, FAS). We hypothesize that LXR activation will be protective against the onset of diabetic nephropathy. My first goal will be to develop a treatment protocol to induce diabetic nephropathy in a wild type (WT) mouse. Dyslipidemia will be induced using a high fat/high cholesterol (HF/HC) diet and hyperglycemia will be induced using streptozotocin (STZ). The basal phenotype of LXR-null mice under the HF/HC + STZ treatment protocol will than be characterized. This will determine whether the loss of LXR increases the susceptibility to diabetic nephropathy. Lastly, the effect of LXR activation on the progression and severity of diabetic nephropathy will be determined using WT mice subjected to HF/HC + STZ treatment in the presence or absence of LXR agonist. This will assess the ability of an LXR agonist to protect the kidney from lipid accumulation and thus prevent progression to diabetic nephropathy. By determining whether LXR activation can modulate lipid accumulation in the kidney, we hope to uncover a new therapeutic target for the treatment of diabetic nephropathy.
Competitiondate
200910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Patel, Monika
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~